Shen, Jianfeng http://orcid.org/0000-0001-9779-6225
Ju, Zhenlin
Zhao, Wei
Wang, Lulu
Peng, Yang
Ge, Zhongqi
Nagel, Zachary D.
Zou, Jun
Wang, Chen
Kapoor, Prabodh
Ma, Xiangyi
Ma, Ding
Liang, Jiyong
Song, Shumei
Liu, Jinsong
Samson, Leona D.
Ajani, Jaffer A.
Li, Guo-Min
Liang, Han http://orcid.org/0000-0001-7633-286X
Shen, Xuetong
Mills, Gordon B.
Peng, Guang
Article History
Received: 28 September 2017
Accepted: 12 March 2018
First Online: 7 May 2018
Competing interests
: G.B.M. has received sponsored research support from Abbvie, AstraZeneca, Critical Outcomes Technology, Horizon Diagnostics, Illumina, Immunomet, Ionis, Karus Therapeutics, Nanostring, Pfizer, Takeda/Millennium Pharmaceuticals, and Tesaro; has ownership interest in Catena Pharmaceuticals, PTV Ventures, and Spindle Top Ventures; and is a consultant/advisory board member of AstraZeneca, Catena Pharmaceuticals, Critical Outcome Technologies, ImmunoMET, Ionis, Medimmune, Nuevolution, Pfizer, Precision Medicine, Signalchem Lifesciences, Symphogen, Takeda/Millennium Pharmaceuticals, and Tarveda. G.P. has received sponsored research support from Pifzer. No potential conflicts of interest were disclosed by the other authors.